Rule 10b5-1 Trading Plans

On May 29, 2026, Dr. Christopher Kenney, the Company’s Chief Medical Officer, adopted a trading plan intended to satisfy the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The plan provides that commencing August 28, 2026, Dr. Kenney may sell up to an aggregate of 26,418 of the Company’s common shares. The plan terminates on the earlier of the date all shares under the trading plan are sold or June 1, 2027.

On June 30, 2026, Andrea DiFabio, the Company’s Chief Legal Officer, adopted a trading plan intended to satisfy the requirements of Rule 10b5-1(c) under the Exchange Act. The plan provides that commencing September 29, 2026, Ms. DiFabio may sell up to an aggregate of 25,402 of the Company’s common shares. The plan terminates on the earlier of the date all shares under the trading plan are sold or July 1, 2027.

The number of shares to be sold in accordance with each of these trading plans is subject to various minimum price targets, or limit prices, being met on each applicable predetermined sale date. In the event the minimum price targets are not met on the applicable predetermined sale date or on any subsequent predetermined sale date, the corresponding shares shall not be sold.